The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, P. W.
Right arrow Articles by Restifo, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, P. W.
Right arrow Articles by Restifo, N. P.

The Journal of Immunology, Vol 156, Issue 1 224-231, Copyright © 1996 by American Association of Immunologists

ARTICLES

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen

PW Chen, M Wang, V Bronte, Y Zhai, SA Rosenberg and NP Restifo
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Recombinant adenovirus (rAd), deleted of critical genes that enable viral replication and replaced with genes encoding heterologous proteins, has been shown to be a safe and effective vector in gene therapy studies. To evaluate a potential role for rAd as an immunogen, we used two different replication-defective type 2 rAds encoding the model Ag, beta-galactosidase (beta-gal). To determine whether rAd elicited the kind of immune responses therapeutic in an anti-tumor setting, the beta-gal-expressing adenocarcinoma, CT26.CL25, was used. Splenocytes from BALB/c mice immunized with 1 x 10(7) infectious units (iu) of rAd demonstrated anti-beta-gal activity after in vitro culture with the relevant L(d) beta-gal peptide. Adoptive transfer of these same splenocytes produced dramatic regression of established pulmonary metastases. However, when tumor-bearing mice were treated with 1 x 10(7) iu of rAd, no reduction in established disease was observed even when rAd was given with exogenous IL-2. To increase the viral dose delivered to each animal, we used an E1-E4-deleted rAd that could be grown to much higher titers. Significant reduction occurred with 10- fold more rAd (1 x10(8) iu) was administered. Exogenous IL-2 administration with 1 x 10(8) iu of rAd resulted in augmentation of this anti-tumor effect. These findings demonstrate that when using a nonreplicating virus, the viral dose is directly related to the immune response generated. These data constitute the first reported use of rAd in the treatment of an established experimental cancer and may have implication for the treatment of human cancer.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini and K. Odunsi
Immunologic Approaches to Ovarian Cancer Treatment
J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Park, M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J. C. Morris, and J. A. Berzofsky
Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas
J. Immunol., April 1, 2005; 174(7): 4228 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Worgall, A. Busch, M. Rivara, D. Bonnyay, P. L. Leopold, R. Merritt, N. R. Hackett, P. W. Rovelink, J. T. Bruder, T. J. Wickham, et al.
Modification to the Capsid of the Adenovirus Vector That Enhances Dendritic Cell Infection and Transgene-Specific Cellular Immune Responses
J. Virol., March 1, 2004; 78(5): 2572 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 Crit. Rev. Oral Biol. Med.Home page
K. Devaraj, M. L. Gillison, and T.-C. Wu
DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. M. Aarts, J. Schlom, and J. W. Hodge
Vector-based Vaccine/Cytokine Combination Therapy to Enhance Induction of Immune Responses to a Self-Antigen and Antitumor Activity
Cancer Res., October 15, 2002; 62(20): 5770 - 5777.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. C. Armstrong, S. Dermime, C. G. Allinson, T. Bhattacharyya, K. Mulryan, K. R. Gonzalez, P. L. Stern, and R. E. Hawkins
Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope
J. Immunol., April 15, 2002; 168(8): 3983 - 3991.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Kershaw, C. Hsu, W. Mondesire, L. L. Parker, G. Wang, W. W. Overwijk, R. Lapointe, J. C. Yang, R.-F. Wang, N. P. Restifo, et al.
Immunization against Endogenous Retroviral Tumor-associated Antigens
Cancer Res., November 1, 2001; 61(21): 7920 - 7924.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Motta, F. Andre, A. Lim, J. Tartaglia, W. I. Cox, L. Zitvogel, E. Angevin, and P. Kourilsky
Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells
J. Immunol., August 1, 2001; 167(3): 1795 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. W. Grosenbach, J. C. Barrientos, J. Schlom, and J. W. Hodge
Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects
Cancer Res., June 1, 2001; 61(11): 4497 - 4505.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. L. Rakhmilevich, M. Imboden, Z. Hao, M. D. Macklin, T. Roberts, K. M. Wright, M. R. Albertini, N.-S. Yang, and P. M. Sondel
Effective Particle-mediated Vaccination against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor
Clin. Cancer Res., April 1, 2001; 7(4): 952 - 961.
[Abstract] [Full Text]

Home page
 BloodHome page
J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas
Blood, March 1, 2001; 97(5): 1370 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Zheng, P. Palese, and A. García-Sastre
Antitumor Properties of Influenza Virus Vectors
Cancer Res., December 1, 2000; 60(24): 6972 - 6976.
[Abstract] [Full Text]

Home page
 BloodHome page
V. Bronte, E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini, P. Zamboni, N. P. Restifo, and P. Zanovello
Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells
Blood, December 1, 2000; 96(12): 3838 - 3846.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D.-W. Liu, Y.-P. Tsao, C.-H. Hsieh, J.-T. Hsieh, J. T. Kung, C.-L. Chiang, S.-J. Huang, and S.-L. Chen
Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth
J. Virol., October 1, 2000; 74(19): 9083 - 9089.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
A. McAllister, A. E. Arbetman, S. Mandl, C. Peña-Rossi, and R. Andino
Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases
J. Virol., October 1, 2000; 74(19): 9197 - 9205.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. P. Wong and R. Levy
Recombinant Adenovirus Vaccine Encoding a Chimeric T-Cell Antigen Receptor Induces Protective Immunity against a T-Cell Lymphoma
Cancer Res., May 1, 2000; 60(10): 2689 - 2695.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
A. Prevost-Blondel, E. Roth, F. M. Rosenthal, and H. Pircher
Crucial Role of TNF-{alpha} in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo
J. Immunol., April 1, 2000; 164(7): 3645 - 3651.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
A. Hernandez and B. M. Evers
Functional Genomics: Clinical Effect and the Evolving Role of the Surgeon
Arch Surg, November 1, 1999; 134(11): 1209 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. Sznol, S. L. Schwarz, P. J. Spiess, et al.
Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine
J. Immunol., August 1, 1999; 163(3): 1690 - 1695.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
T.R.J. Evans and S.B. Kaye
Vaccine therapy for cancer—fact or fiction?
QJM, June 1, 1999; 92(6): 299 - 307.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
E. A. Hirschowitz and R. G. Crystal
Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Metastases
Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 935 - 941.
[Abstract] [Full Text]

Home page
 J. Exp. Med.Home page
S. Sarma, Y. Guo, Y. Guilloux, C. Lee, X.-F. Bai, and Y. Liu
Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo
J. Exp. Med., March 1, 1999; 189(5): 811 - 820.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Tuting, C. C. Wilson, D. M. Martin, Y. L. Kasamon, J. Rowles, D. I. Ma, C. L. Slingluff Jr., S. N. Wagner, P. van der Bruggen, J. Baar, et al.
Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-{alpha}
J. Immunol., February 1, 1998; 160(3): 1139 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. E. M. Toes, R. C. Hoeben, E. I. H. van der Voort, M. E. Ressing, A. J. van der Eb, C. J. M. Melief, and R. Offringa
Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
PNAS, December 23, 1997; 94(26): 14660 - 14665.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. B. Caspar, S. Levy, and R. Levy
Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations
Blood, November 1, 1997; 90(9): 3699 - 3706.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
W. Song, H.-L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A.S. Moore, and R. G. Crystal
Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity
J. Exp. Med., October 20, 1997; 186(8): 1247 - 1256.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.